阿糖腺苷联合核黄素磷酸钠治疗疱疹性咽峡炎疗效观察

Observation of curative effect by vidarabine combined with riboflavin sodium phosphate in the treatment of herpangina

目的探讨阿糖腺苷联合核黄素磷酸钠治疗疱疹性咽峡炎的疗效。方法 80例疱疹性咽峡炎患儿,随机分为治疗组与对照组,各40例。治疗组患儿给予静脉滴注阿糖腺苷联合核黄素磷酸钠治疗,对照组患儿给予静脉滴注利巴韦林治疗,观察两组患儿的临床治疗效果。结果治疗组患儿治疗总有效率为87.5%,明显高于对照组的67.5%,差异具有统计学意义(P<0.05)。治疗组患儿退热时间、疱疹及溃疡消失时间分别为(1.8±0.8)、(2.6±0.8)d,明显短于对照组的(3.0±0.8)、(4.1±0.7)d,差异具有统计学意义(P<0.05)。治疗组患儿不良反应发生率为12.5%,与对照组的20.0%比较,差异无统计学意义(P>0.05)。结论阿糖腺苷联合核黄素磷酸钠治疗疱疹性咽峡炎安全有效,临床效果好,值得推广。

Objective To investigate curative effect by vidarabine combined with riboflavin sodium phosphate in the treatment of herpangina. Methods A total of 80 children patients with herpangina were randomly divided into treatment group and control group, with 40 cases in each group. The treatment group received vidarabine combined with riboflavin sodium phosphate by intravenous drip for treatment, and the control group received ribavirin by intravenous drip for treatment. Observation was made on clinical effects between the two groups. Results The treatment group had obviously higher total effective rate in treatment as 87.5% than 67.5% in the control group, and the difference had statistical significance （P〈O.05）. The treatment group had fever subsidence time and disappearance time of herpes and ulcer respectively as （1.8 - 0.8） and （2.6 ± 0.8） d, which were much shorter than （3.0 ± 0.8） and （4.1±0.7） d in the control group, and their difference had statistical significance （P〈0.05）. The treatment had incidence of adverse reactions as 12.5%, which was 20.0% in the control group, and the difference had statistical significance （P〉0.05）. Conclusion Combination of vidarabine and riboflavin sodium phosphate is safe and effective in treating herpangina with excellent clinical effect. It is worth promoting.